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ABSTRACT: Mutations in the mitochondrial genome, and
in particular the mt-tRNAs, are an important cause of hu-
man disease. Accurate classification of the pathogenicity of
novel variants is vital to allow accurate genetic counseling
for patients and their families. The use of weighted crite-
ria based on functional studies—outlined in a validated
pathogenicity scoring system—is therefore invaluable in
determining whether novel or rare mt-tRNA variants
are pathogenic. Here, we describe the identification of
nine novel mt-tRNA variants in nine families, in which
the probands presented with a diverse range of clinical
phenotypes including mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes, isolated progres-
sive external ophthalmoplegia, epilepsy, deafness and
diabetes. Each of the variants identified (m.4289T>C,
MT-TI; m.5541C>T, MT-TW; m.5690A>G, MT-
TN; m.7451A>T, MT-TS1; m.7554G>A, MT-
TD; m.8304G>A, MT-TK; m.12206C>T, MT-TH;
m.12317T>C, MT-TL2; m.16023G>A, MT-TP)
was present in a different tRNA, with evidence in
support of pathogenicity, and where possible, details
of mutation transmission documented. Through the
application of the pathogenicity scoring system, we have
classified six of these variants as “definitely pathogenic”
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mutations (m.5541C>T, m.5690A>G, m.7451A>T,
m.12206C>T, m.12317T>C, and m.16023G>A),
whereas the remaining three currently lack sufficient
evidence and are therefore classed as ‘possibly pathogenic’
(m.4289T>C, m.7554G>A, and m.8304G>A).
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Introduction
Mutations in the mitochondrial genome (mtDNA) give rise to
a clinically and biochemically heterogeneous range of genetic dis-
orders affecting children and, perhaps more significantly, adults
[Schon et al., 2012; Tuppen et al., 2010]. Both the diagnosis of
mitochondrial disease and the molecular characterization of un-
derlying pathogenic mutations are complicated by the variability in
penetrance and tissue specificity observed even between close family
members, aswell as the lackof a consistent genotype–phenotype cor-
relation [McFarland et al., 2010; Ylikallio and Suomalainen, 2012].
Comprehensive databases of reported mutations, polymorphisms
and their supportingdata (e.g.,MitoMAP,www.mitomap.org [Ruiz-
Pesini et al., 2007]) as well as tools such as pathogenicity scoring
systems [Mitchell et al., 2006; Yarham et al., 2011] are therefore in-
valuable when determining the pathogenic role ofmtDNA sequence
variants [Elson et al., 2012].
Determining the pathogenic nature of a novel or rare mtDNA
variant is particularly problematic for mt-tRNA variants. Mt-tRNA
pointmutations have been associated with a diverse range of clinical
phenotypes including epilepsy, deafness, diabetes, ophthalmopare-
sis, myopathy, cardiomyopathy, and encephalopathy [Florentz et al.,
2003; Yarham et al., 2010]. Over 200 mt-tRNA point mutations
have been linked to mitochondrial disease but less than half of these
have sufficient evidence for a classificationof “definitely pathogenic”
[Yarhamet al., 2011]. Although somemt-tRNAmutations are found
C© 2013 WILEY PERIODICALS, INC.
relatively often in patients (e.g. m.3243A>G andm.8344A>G), most
are rare, having only ever been identified in one or two families
[Ruiz-Pesini et al., 2007; Yarham et al., 2010]. Mt-tRNA point mu-
tations typically cause a loss of mt-tRNA stability leading to de-
fective mitochondrial translation and a combined respiratory chain
deficiency. Potential mechanisms include aberrant processing of the
mRNAtranscript byRNasesP andZL, impairedpost-transcriptional
mt-tRNAmodification (e.g., specific base modifications, 3′-end ad-
dition of the –CCA sequence and mt-tRNA aminoacylation) and
compromised interaction of the mt-tRNA with both mtEF-Tu (mi-
tochondrial elongation factor Tu) and the mitoribosome [Levinger
et al., 2004].
Determining whether an identified mt-tRNA variant is in fact
the pathogenic cause of the observed clinical phenotype is difficult,
partly as a result of the observed genotype–phenotype heterogene-
ity in mitochondrial disease. However, the reliability of such as-
sessment has been improved by the development and revision of a
pathogenicity scoring system consisting of a number of weighted
criteria [Yarham et al., 2011]. The gold-standard studies in par-
ticular provide crucial functional evidence; for heteroplasmic mu-
tations, single-fiber studies investigate mutation segregation with
biochemical deficiency, and for homoplasmic mutations, North-
ern blot analyses assess variations in mt-tRNA steady-state levels
[McFarland et al., 2004].
It was speculated over a decade ago that wemight soon be “scrap-
ing the bottom of the barrel” with respect to identifying novel
pathogenic mtDNA mutations and elucidating their importance
in human pathology [DiMauro and Andreu, 2000]. However, in
this study, we present clinical, histochemical, and molecular genetic
data confirming the identification of novel heteroplasmic mt-tRNA
variants in each of nine unrelated patients who present with a di-
verse range of clinical features. Based on the robust criteria of the
pathogenicity scoring system, the evidencewe present here confirms
six of these variants as “definitely pathogenic” and the remaining
three as “possibly pathogenic,” affirming mt-tRNAmutations as an
important cause of human mitochondrial disease.
Materials and Methods
Patients
The patients presented here were identified in the clinic as
having suspected mitochondrial disease and were referred to the
UK NHS Highly Specialised Services Diagnostic Laboratory in
Newcastle upon Tyne. Informed ethical consent was obtained for
further testing through the acquisition of a skeletal muscle biopsy.
The clinical phenotypes for each of the nine patients studied are
described in Table 1, with further details provided in the Supporting
Information (Supp. Document S1). Each patient harbored a single,
novel mt-tRNA variant in a different mt-tRNA gene, and there was
considerable diversity in the clinical presentations of the disease.
Family histories are indicated, along with the details of the mtDNA
haplogroup of each patient and heteroplasmic mutation loads in a
variety of patient and familial tissue samples (e.g., muscle, blood,
urine, and buccal epithelial cells).
Histology and Histochemistry
Standard histological (Haematoxylin & Eosin, modified Go-
mori trichrome staining) and histochemical (cytochrome c oxi-
dase [COX], succinate dehydrogenase [SDH], and sequential COX–
SDH) analyses of proband muscle biopsies (where available) were
performedon fresh-frozen skeletalmuscle sections (10μm), accord-
ing to established protocols [Old and Johnson, 1989]. Individual
COX-positive and COX-deficient fibers were isolated by laser mi-
crodissection and lysed to obtain total cellular DNA for single-fiber
mutation segregation studies.
Molecular Genetic Studies
Total DNA was extracted from all available tissues by standard
procedures, and mtDNA rearrangements were excluded by long-
range PCR. Direct sequencing of the entire mitochondrial genome
was then performed on homogenate skeletal muscle DNA. Total
DNAwas additionally extracted fromavailable tissues obtainedwith
consent, from appropriate maternal relatives.
Known polymorphisms were excluded through the searching
of the MitoMAP (www.mitomap.org) [Ruiz-Pesini et al., 2007]
and mtDB (http://www.mtdb.igp.uu.se/) databases [Ingman
and Gyllensten, 2006]. Haplogroup analysis was performed
using Haplogrep (http://haplogrep.uibk.ac.at/) and Phylotree
(http://www.phylotree.org/) [Kloss-Brandsta¨tter et al., 2011; van
Oven and Kayser, 2009].
Assessment of Mutation load by Quantitative
Pyrosequencing
The mtDNA mutation load in all available homogenate tissue
DNA and individual COX-positive and COX-deficient fibers was
assessed by quantitative pyrosequencing. The Pyromark Assay De-
sign Software v.2.0 (Qiagen, Crawley, West Sussex, UK) was used
to design locus-specific PCR and pyrosequencing primers (Supp.
Table S1) for each variant and pyrosequencing was performed on
the Pyromark Q24 platform according to the manufacturer’s pro-
tocol. Quantification of the heteroplasmy level of each variant was
achieved using Pyromark Q24 software to directly compare the rel-
evant peak heights of both the wild-type and mutant nucleotides at
the relevant position [White et al., 2005].
Quantification of mt-tRNA Steady-State Levels by
High-Resolution Northern Blot
High-resolution Northern blotting to assess mt-tRNAHis steady-
state levels in patient skeletal muscle was performed as previously
described [Taylor et al., 2003]. Probeswere generated by PCR ampli-
fication across the mt-tRNALeu(UUR) (75 bp) and mt-tRNAHis genes
(69 bp). A 154 bp tRNALeu(UUR) probe was generated using the for-
ward primer L3200 (positions 3,200–3,219) and the reverse primer
H3353 (positions 3,353–3,334); a 120bpmt-tRNAHis probewas gen-
erated using the forward primer L12086 (positions 12,086–12,104)
and the reverse primer 12,205 (positions 12,205–12,186) (GenBank
Accession number NC 012920.1 for human mtDNA).
Assigning Pathogenicity to mt-tRNA Variants
The pathogenicity classification of each of the mt-tRNA variants
identified and characterized in this study, was assigned using an
updated version of a previously validated scoring system [Yarham
et al., 2011]. This pathogenicity scoring system employs a number
of weighted criteria covering a range of molecular, functional, and
genetic data, from which an overall pathogenicity score (out of a
total of 20 points) can be obtained.
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Figure 1. Sequential COX–SDH histochemistry. Sequential cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) histochemistry
was performed on skeletal muscle biopsies from all patients with the exception of patients 1 and 6. A mosaic pattern of COX activity is visible in
each of the images, with COX-deficient fibers shown in blue and COX-positive fibers shown in brown. For patient 6, the individual COX histochemical
reaction demonstrates a large number of COX-deficient fibers.
Variants were classified as “definitely pathogenic” with a score
of ≥11 points including evidence from one or more of the “gold-
standard” investigations: segregation of the variant with a biochem-
ical deficiency in single-fibers, high-resolution Northern blotting
analysis of mt-tRNA steady-state levels, or transmitochondrial cy-
brid studies. Variants were classified as “probably pathogenic” with
a score of ≥11 points but lacking evidence from a “gold-standard”
investigation, “possibly pathogenic” with a score of 7–10 points and
a “neutral polymorphism” with a score of ≤6 points.
Results
Histochemistry
Dual enzyme histochemistry performed on each of the proband’s
skeletal muscle biopsies where available, revealed a significant num-
ber of COX-deficient fibers (Fig. 1), several of which were accompa-
nied by evidence of subsarcolemmal mitochondrial accumulation
associated with ragged-red fibers, which is indicative of mitochon-
drial disease. For patient 6, muscle was not available to study using
COX–SDHhistochemistry but the individual COX reaction demon-
strated a large number of COX-deficient fibers.
Molecular Genetic Studies
Long-range PCR of skeletal muscle DNA samples from each of
the nine patients excluded the presence of large-scale mtDNA rear-
rangements. Direct sequencing of the entire mitochondrial genome
revealed a previously unreported substitution in an MT-T gene in
each patient (Table 1), which appeared heteroplasmic on the chro-
matogram (Supp. Fig. S1). The substitutions were confirmed to be
novel variants absent from the specific haplogroup of each proband
(Table 1), and were not identified on databases of known polymor-
phisms.
The nine identified variants were each located within a different
mt-tRNA and, as illustrated in Figure 2, are located in a variety of
structural stem and loop regions. Each of the variants was found
at a position that is highly conserved across evolution according
to the consensus panel of species [Yarham et al., 2012], except for
them.4289T>Cvariantwhich showsmoderate conservation and the
m.7554G>A variant which shows poor conservation (Supp. Fig. S2).
All nine novel mtDNA variants have been submitted for inclusion
within the MitoMAP database.
Mutation Heteroplasmy and Inheritance Patterns
Eachof thenine identified variantswas shown tobeheteroplasmic
through quantitative pyrosequencing analysis of mutation load in
homogenate DNA from all available patient tissues. Each variant
was assessed in skeletal muscle from the patient, whereas blood,
urine, fibroblasts, and buccalmucosawere also testedwhere possible
(Table 1).
The inheritance pattern of each variant was determined through
an analysis of mutation load in noninvasive tissues (blood, urine,
and buccal mucosa) from maternal relatives, where available. As
described inTable 1, fourof the variantswere shown tobematernally
inherited, three appear to be de novo and two remain undetermined
due to a lack of familial samples for analysis.
Segregation of mt-tRNA Mutations with Biochemical
Deficiency
Single-fiber analysis was performed to determine whether the
mutation load in individual COX-positive and COX-deficient fibers
correlated with the observed biochemical phenotype (Fig. 3) in
each of the probands (with the exception of patients 1 and 6, from
whom amuscle biopsy block was unavailable). Mutation loads were
found to be significantly higher (P < 0.05, two-tailed t test) in the
COX-deficient fibers (n≥ 9) compared with the COX-positive fibers
(n ≥ 10) (±SD) (Table 2), confirming segregation of the identified
mtDNA variants with respiratory chain deficiency in each patient.
Quantification of mt-tRNAHis Steady-State Levels
Although statistically significant, the segregation of the
m.12206C>T variant with biochemical deficiency in single fibers
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Figure 2. Location of mt-tRNA variants. The location of each of the identified mt-tRNA variants within the tRNA cloverleaf structure is shown.
Each of the nine novel variants occurs within a different mt-tRNA, in a variety of stems, loops, and other regions. The affected position and the
substitution that occurs are highlighted in bold.
(Fig. 3) was less apparent than the segregation observed with the
other variants. Consequently, high-resolution northern analysis of
mt-tRNAHis steady-state levels was performed in addition to the
single fiber analysis. The steady-state level of mt-tRNAHis was found
to be ∼25% of the control mt-tRNAHis steady-state levels in this
patient’s skeletal muscle (Supp. Fig. S3).
Discussion
Mitochondrial tRNA point mutations are associated with a di-
verse range of clinical phenotypes that show only a limited corre-
lation with genotype, and this considerable heterogeneity greatly
complicates the diagnosis of mitochondrial disease. Here we de-
scribe the characterization of nine novel heteroplasmic mt-tRNA
variants identified in nine unrelated patients. Each variant oc-
curred in a different mt-tRNA and there was a range of associ-
ated clinical presentations including (but not limited to) epilepsy,
diabetes, CPEO, and deafness (Table 1 and Supp. Document S1).
This diversity reaffirms the heterogeneity seen in the phenotype–
genotype relationship of mt-tRNA mutations, which arises due
to the complex interactions between nuclear and mitochondrial
genetics, the dramatic variations in tissue segregation of hetero-
plasmic mt-tRNA point mutations, and the threshold effect for
pathogenicity. The importance of appropriate tissue selection is
also demonstrated; for example, although the m.7554G>A variant
in patient 5 was found at a level of 87% in skeletal muscle, it was
detected at considerably lower levels in the other tissues investi-
gated, with levels of 22% in urine, 10% in buccal mucosa, and 6% in
blood.
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Figure 3. Single fiber mutation load segregation. This graph shows the mutation load measured in individual COX-positive (closed circles) and
COX-deficient fibers (open circles) laser-micro dissected from a skeletal muscle biopsy taken from all the patients with the exception of patients
1 and 6, which were omitted due to a lack of available tissue. In each patient studied, the identified variant segregates with the biochemical
deficiency.
Table 2. Single Fiber Mutation Load Data
Percentage mutation load
Patient mt-tRNA mutation COX-positive fibers COX-deficient fibers P value
2 m.5541C>T 51.4 ± 28.1 90.0 ± 2.7 0.0003
3 m.5690A>G 27.9 ± 31.3 86.8 ± 18.3 <0.0001
4 m.7451A>T 14.6 ± 25.1 97.4 ± 3.8 <0.0001
5 m.7554G>A 17.5 ± 13.2 94.0 ± 8.7 <0.0001
7 m.12206C>T 73.8 ± 31.8 97.1 ± 1.5 0.0391
8 m.12317T>C 31.1 ± 32.4 87.7 ± 8.3 <0.0001
9 m.16023G>A 60.1 ± 25.3 86.9 ± 11.3 0.0005
The percentage mutation load in individual COX-positive and COX-deficient fibers
from the seven patients investigated (plus or minus the standard deviation) is shown.
All novel mt-tRNA variants showed significant segregation with the biochemical defect
(P values) at the 95% confidence level.
Assigning Pathogenicity
The pathogenicity classification of these nine novel variants was
determined using the mt-tRNA point mutation pathogenicity scor-
ing system [Yarham et al., 2011], which outlines a number of
weighted criteria. There have been no previous reports of the nine
variants, all are heteroplasmic, and all are absent from haplogroup-
matched controls. Sequential COX–SDH histochemistry revealed
COX-deficient fibers in skeletal muscle biopsies from all patients
(Fig. 1) with the exception of two—patient 1 (m.4289T>C) and pa-
tient 6 (m.8304G>A)where appropriate tissuewasunavailable, how-
ever forpatient 6numerousCOX-deficient skeletalmusclefibers had
been previously identified using an individual COX histochemical
reaction .
Evolutionary conservation of the affected positions was as-
sessed using the consensus panel of organisms [Yarham et al.,
2012]; m.5541C>T, m.5690A>G, m.7451A>T, m.8304G>A and
m.16023G>A all affect highly conservedWatson–Crick pairs within
stem structures; m.12317T>C affects a highly conserved base in
the T loop; m.12206C>T affects the highly conserved discriminator
base; m.4289T>C affects a moderately conserved base in the anti-
codon stem andm.7554G>A affects a less conserved base within the
anticodon stem (Supp. Figs. S1 and S2).
Importantly, single-fiber analysis in all patients, with the ex-
ception of patients 1 and 6 for whom orientated muscle blocks
were not available, demonstrated a statistically significant seg-
regation of mutation load with biochemical deficiency (Fig. 3).
In addition, high-resolution northern analysis showed that mt-
tRNAHis steady-state levels are reduced in skeletal muscle from
patient 7 compared with controls (Supp. Fig. S3). On the basis
of this evidence, m.5541C>T (11 points), m.5690A>G (11 points),
m.7451A>T (11 points), m.12206C>T (16 points), m.12317T>C (11
points), and m.16023G>A (11 points) can all be considered “def-
initely pathogenic” mutations and are responsible for the clinical
presentations observed in these patients.
Despite evidence supporting pathogenicity from single-fiber in-
vestigations, the lack of both evolutionary conservation and sup-
portive evidence from biochemical analyses of respiratory chain
complex activities means that the m.7554G>A (9 points) cannot
currently be considered “definitely pathogenic,” but is classified as
“possibly pathogenic.” However, a future report of this variant in a
separate family would be sufficient for reclassification as “definitely
pathogenic.”
Neither m.4289T>C (7 points) nor m.8304G>A (8 points) have
evidence from “gold-standard” functional investigations, and both
must consequently be classified as “possibly pathogenic.” Further in-
vestigation is therefore required in order to confirm the pathogenic
nature of these two variants. Despite the obvious benefits of re-
porting “definitely pathogenic” mutations, other identified variants
that currently lack sufficient evidence should also be reported, along
with the appropriate classification as this will enable future reports
with additional studies to confirm pathogenicity.
Molecular Impact
Both m.4289T>C and m.5541C>T occur in genes known to be
susceptible to pathogenic mutations (Supp. Table S2), and are lo-
cated at the Watson-Crick pair adjacent to the anticodon loop
(Fig. 2). This position has previously been associated with disease
in other mt-tRNAs (m.1630A>G in mt-tRNAVal [Glatz et al., 2011;
Horvath et al., 2009a] and m.5628T>C in mt-tRNAAla [Spagnolo
et al., 2001]), and it seems likely that such a mutation might disrupt
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the secondary structure of the anticodon arm, potentially therefore
impacting upon the codon–anticodon interaction. Them.5690A>G
(mt-tRNAAsn) and m.7554G>A (mt-tRNAAsp) variants also occur
within the anticodon stem, but in these instances, at the penulti-
mate Watson–Crick pair before the anticodon loop (Fig. 2). Again,
this base-pair has been shown to contain pathogenic mutations in
other mt-tRNAs including mt-tRNAPhe (m.617G>A [Iizuka et al.,
2009]) andmt-tRNAIle (m.4298G>A [Crimi et al., 2004; Taylor et al.,
1998]), indicating the impact of secondary structure disruption on
pathogenesis. However, although a number of definitely pathogenic
mutations have been found inmt-tRNAAsn, none, including themu-
tation reported here, have yet been confirmed inmt-tRNAAsp (Supp.
Table S2).
The m.8304G>A variant in a commonly mutated mt-tRNA gene,
MT-TK (Supp. Table S2), is located in the D stem (Fig. 2), at a
position involved in tertiary structure formation [Helm et al., 2000].
Previously identified pathogenic mutations at this position include
m.5521G>A (mt-tRNATrp [Silvestri et al., 1998]) and m.12147G>A
(mt-tRNAHis [Melone et al., 2004; Taylor et al., 2004]), confirming
the vulnerability of this position. Interestingly, the proband in this
case presentedwith epilepsy, similar to patientswith them.8344A>G
MT-TKmutation associated with the MERRF phenotype.
The mutation m.16023G>A occurs at position 1 in mt-tRNAPro
(Fig. 2), and although to date, no other definitely pathogenic muta-
tionshavebeen identified at this position,m.8363G>A(mt-tRNALys)
does occur at its cognate pair [Ozawa et al., 1997; Santorelli et al.,
1996]. Given the location of this mutation at the end of the accep-
tor stem, pathogenesis may result from disruption of either post-
transcriptional processing of the mt-tRNA from the transcript, or
aminoacylation.
The m.7541T>A (mt-tRNASer(UCN)) mutation is located in the
middle of the acceptor stem (Fig. 2) at a position where pathogenic
mutations have been identified in other mt-tRNAs including
m.642T>C inmt-tRNAPhe [Valente et al., 2009] andm.12201T>C in
mt-tRNAHis [Yan et al., 2011]). The conserved nature of the pairing
at this position suggests that may be important for the maintenance
of mt-tRNA secondary structure, and potentially for the binding of
aminoacyl-tRNA synthases.
Them.12206C>Tmutation occurs at the discriminator base (Fig.
2), and is therefore likely to have a direct impact upon processing
of the mtDNA transcript during translation, nucleotidyltransferase
activity and aminoacylation. Interestingly, the only other confirmed
pathogenic mutation at this position (m.14674T>C in mt-tRNAGlu
[Horvath et al., 2009b; Uusimaa et al., 2011]) was found to have
lower tRNA steady-state levels rather than excess unprocessed in-
termediates. This might be explained by a loss of stability con-
ferred by aminoacylation, although a recent study of mitochondrial
methionyl-tRNA formyltransferase (MTFMT) activity suggests that
mt-tRNAs may actually primarily exist in the uncharged form, at
least in the case of mt-tRNAMet [Tucker et al., 2011].
Finally, the m.12317T>Cmutation occurs in the T loop, adjacent
to the T stem (Fig. 2). This region of mt-tRNAs is highly vari-
able, yet the high evolutionary conservation of this position (Supp.
Fig. S2) implies an important role for this particular base. Given
that this position in mt-tRNALeu(CUN) is involved in tertiary interac-
tions that confer a structurally important turn in the phosphodiester
backbone, a substitution at this position may impact upon the es-
sential shape of the anticodon loop.
The molecular mechanisms by which the mutations described
here actually cause disease are only speculation at this stage, based
upon the location of the changes and observations made about
similarly positioned mutations in other mt-tRNAs. Given the iden-
tification of mutations in genes encoding proteins involved in mt-
tRNA modification as a cause of mitochondrial disease (e.g., PUS1
[Bykhovskaya et al., 2004], TRMU [Zeharia et al., 2009], MTO1
[Ghezzi et al., 2012], MTFMT [Tucker et al., 2011], the disrup-
tion of these post-transcriptional modifications represents a major
consideration for potential diseasemechanisms.Modifications such
as pseudouridine and methyl groups are highly prevalent in tRNA
species and are fundamental to structure and function—for in-
stance modification of position 34 (the wobble position) is crucial
to determining mt-tRNA specificity [Suzuki et al., 2011]. Of the
mutations reported here, onlym.8304G>A is known to be located at
a position normally modified (m2G10), although some of the oth-
ers occur at residues known to be modified in different mt-tRNAs
(not all species have yet been characterized). The impact of a loss
of this particular modification is currently unclear but structural
disruption seems plausible. Further functional studies are therefore
essential to fully elucidate themechanisms bywhich thesemutations
result in disease.
Clinical and Diagnostic Implications
Point mutations within mt-tRNA genes represent the most com-
mon group of mtDNAmutations to cause human disease, yet many
questions remain with regards understanding the critical factors
which underlie their clinical expression, inheritance, and even the
permissive susceptibility of these genes to mutation. We present
data on nine novel heteroplasmic mt-tRNA variants, each result-
ing in a different clinical phenotype, highlighting the lack of a firm
genotype–phenotype correlation inmt-tRNAdisease. Furthermore,
each novelmutation affects a differentmt-tRNAmolecule, although
an assessment of all well-characterized mt-tRNA mutations associ-
ated with disease reveals that some mt-tRNAs—in particular mt-
tRNALeu(UUR), mt-tRNAIle, and mt-tRNALys—harbor more muta-
tions than others (Supp. Fig. S2).
Other questions persist; recent data have suggested that those
mt-tRNAmutations which exert a major biochemical phenotype in
dividing cells are unlikely to be inherited and transmitted through
the female germline [Elson et al., 2009], yet what are the factors
that determine how these mutations arise sporadically? The impor-
tance of sequencing mtDNA from a clinically relevant tissue and
extensive screening of maternally related individuals to investigate
mutation inheritance and segregation are highlightedwithin this ar-
ticle. Furthermore, although there are some loose correlations with
clinical phenotype and mutation of a specific mt-tRNA gene (e.g.,
mt-tRNAIle mutations and cardiomyopathy, mt-tRNALys mutations
and the MERRF phenotype), the data presented here reminds us
how phenotypically diverse mt-tRNAmutations are and that only a
small number (as exemplified by the m.3243A>G and m.8344A>G
mutations) account for a substantial proportion of all mtDNA dis-
ease diagnoses, whereas others are limited to singleton families.
What makes a particular site or nucleotide within an mt-tRNA
molecule vulnerable to mutation? Based on our reanalysis of the
pathogenicity of reported human mt-tRNA mutations [Yarham
et al., 2011], we have updated the analysis of McFarland and col-
leagues who reported mt-tRNA mutation “hotspots” in both the
anticodon and acceptor stems, on the basis that 73% of all reported
mt-tRNAmutations occurred in stem structures, with 94% of these
disruptingWatson–Crick base pairing [McFarland et al., 2004]. The
current dataset confirms that these trends hold true, with 67% of
the 116 reported mt-tRNA mutations which have been reclassified
as “definitely pathogenic” occurring with the stem structures and
of these, 90% result in the disruption of Watson–Crick base pairing
(Fig. 4).
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Figure 4. Location of “definitely pathogenic” mutations across the mt-tRNAs. The number of “definitely pathogenic” mt-tRNA point mutations
found at various locations throughout the cloverleaf are shown by the use of a gradient color scale; lighter colors equate to fewer mutations,
whereas darker colors specify more mutations. “Definitely pathogenic” mutations occur mainly in the stems and to a lesser degree in the loops
with the notable exception of a position in the DHU-loop, which includes the m.3243A>G MT-TL1 mutation, and the third base of the anticodon.
Conclusion
Over 200 mitochondrial tRNA variants have now been reported.
The fact that only half of these variants have sufficient evidence to
be “definitely pathogenic,” demonstrates the difficulties faced when
characterizing potentially pathogenic variants. The vast heterogene-
ity in the phenotype–genotype relationship is demonstrated by the
nine patients reported here, making accurate diagnosis immensely
difficult and reaffirming the importance of meticulous clinical as-
sessment, appropriate tissue selection for analysis, and comprehen-
sive laboratory investigations. The variants reported here should
be added to the library of mt-tRNA variants associated with dis-
ease, contributing to our knowledge of this field and confirming
mt-tRNA mutations as an important subgroup of human genetic
disorders [Schon et al., 2012].
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